-
Product Insights
BP Gelsenkirchen Complex, Germany
Each petrochemical complex profile includes core details such as complex name, location, complex status, start year, annual petrochemical capacity (mtpa) for the period 2015-2030, key feedstock, key products produced, operator, technology, key products capacity and capacity share of the total annual capacity of the complex. We also provide contractor details such as EPC/Design & FEED contractors for the petrochemical complex. This is an on-demand report that will be delivered upon request. The report will be delivered within 1 business day...
-
Company Insights
NewBP Plc – Digital Transformation Strategies
BP Digital Transformation Strategies Report Overview BP has been focusing on AI driven tools as a part of its digital transformation strategies. The annual ICT spending of BP was estimated at $879.5 million for 2023. A major share of this spending is earmarked for acquiring ICT services, software, and hardware from vendors. BP is an integrated oil and gas company that produces fuel, energy, lubricants, and petrochemicals. Total ICT Spending 2023 $879.5 million ICT Spend by Function Communications, Data Center,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BP-1.3656B in Fatigue
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.BP-1.3656B in FatigueDrug Details:BP-1.3656B is under development for the treatment of central nervous system disorders including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BP-1.7881 in Eosinophilic Esophagitis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.BP-1.7881 in Eosinophilic EsophagitisDrug Details:BPI-7881A is under development for the treatment of atopic dermatitis and eosinophilic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BP-1.4979 in Restless Legs Syndrome
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BP-1.4979 in Restless Legs Syndrome Drug Details: BP-1.4979 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BP-1.4979 in Binge Eating Disorder
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BP-1.4979 in Binge Eating Disorder Drug Details: BP-1.4979 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BP-1002 in Mantle Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BP-1002 in Mantle Cell Lymphoma Drug Details: BP-1002 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BP-102 in Recurrent Glioblastoma Multiforme (GBM)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BP-102 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: BP-102 is under investigation for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BP-1002 in Cutaneous T-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BP-1002 in Cutaneous T-Cell Lymphoma Drug Details: BP-1002 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BP-1.7881 in Atopic Dermatitis (Atopic Eczema)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.BP-1.7881 in Atopic Dermatitis (Atopic Eczema)Drug Details:BPI-7881A is under development for the treatment of atopic dermatitis...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BP-1002 in Relapsed Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BP-1002 in Relapsed Acute Myeloid Leukemia Drug Details: BP-1002 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BP-1002 in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BP-1002 in Refractory Acute Myeloid Leukemia Drug Details: BP-1002 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BP-1002 in Peripheral T-Cell Lymphomas (PTCL)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BP-1002 in Peripheral T-Cell Lymphomas (PTCL) Drug Details: BP-1002 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BP-1002 in Marginal Zone B-cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BP-1002 in Marginal Zone B-cell Lymphoma Drug Details: BP-1002 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BP-1002 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BP-1002 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drug Details: BP-1002 is under development for the...
-
Product Insights
BP – Tianjin Lubricants Blending Plant – Tianjin
Equip yourself with the essential tools needed to make informed and profitable decisions with our BP - Tianjin Lubricants Blending Plant - Tianjin report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the...
-
Product Insights
BP – Retford Solar Farm 61MW – Nottinghamshire
Equip yourself with the essential tools needed to make informed and profitable decisions with our BP - Retford Solar Farm 61MW - Nottinghamshire report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the...
-
Product Insights
BP – Naperville Plastic Recycling Plant – Illinois
Equip yourself with the essential tools needed to make informed and profitable decisions with our BP - Naperville Plastic Recycling Plant - Illinois report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the...
-
Product Insights
BP – TOPR Offshore Pipeline – Trinidad and Tobago
Equip yourself with the essential tools needed to make informed and profitable decisions with our BP - TOPR Offshore Pipeline - Trinidad and Tobago report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
BP – Kwinana Renewable Fuels Development – Western Australia
Equip yourself with the essential tools needed to make informed and profitable decisions with our BP - Kwinana Renewable Fuels Development - Western Australia report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.